CYPT Rated "LONG TERM BUY" by Capstone Investments -30 march 04:
march 30, 2004 12:34 PM US Eastern Timezone
ADDING and REPLACING CapStone Investments Announces Investment Opinion on Calypte Biomedical
NOTE TO EDITORS: The following is an investment opinion issued
by CapStone Investments
SAN DIEGO--(BUSINESS WIRE)--march. 30, 2004--Add after Calypte Biomedical:
(OTCBB:CYPT - News)
The corrected release reads:
CAPSTONE INVESTMENTS ANNOUNCES INVESTMENT OPINION ON CALYPTE BIOMEDICAL
CapStone Investments Initiates Coverage of Calypte Biomedical with a "Long-Term Buy" Recommendation and $2 Price Target
CapStone Investments, a full-service investment firm, announced today that it has initiated coverage of Calypte Biomedical (OTCBB:CYPT - News) with a "Long-Term Buy" and a price target of $2. The report was written by Jason Diamond, the Director of Research.
CapStone Investments makes its research reports available in real-time to institutional investors through Multex at www.multex.com, Thomson Financial-First Call at www.firstcall.com and Research Edge at www.zackspro.com/edge, a product of Zack's Investment Research Inc.
About CapStone Investments
CapStone Investments (www.capstoneinvestments.com), based in San Diego, Calif., with its Research Division in Milwaukee, Wis., is a full-service investment firm, servicing a multi-billion dollar institutional account base. CapStone Investments is a member of the National Association of Securities Dealers (NASD), the Securities Investment Protection Corporation (SIPC) and the Municipal Securities Rulemaking Board (MSRB). CapStone Institutional Services (CapStone) is a division of CapStone Investments. CapStone is a dedicated alternative investment specialist focused on providing comprehensive service to the alternative investment manager.